Daily Stock Analysis, AGIO, Agios Pharmaceuticals Inc, priceseries

Agios Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
32.43
Close
33.99
High
34.31
Low
32.21
Previous Close
32.43
Daily Price Gain
1.56
YTD High
34.31
YTD High Date
Nov 12, 2019
YTD Low
32.21
YTD Low Date
Nov 12, 2019
YTD Price Change
1.56
YTD Gain
4.81%
52 Week High
34.31
52 Week High Date
Nov 12, 2019
52 Week Low
0.00
52 Week Low Date
Wrong Month 0, 0
52 Week Price Change
33.99
52 Week Gain
inf%
Company Information
Stock Symbol
AGIO
Exchange
NasdaqGS
Company URL
http://www.agios.com
Company Phone
617-649-8600
CEO
David Paul Schenkein
Headquarters
Massachusetts
Business Address
88 SIDNEY STREET, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001439222
About

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in applying scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism. Its products include IDH1 AND IDH2, PKR, II D-2 hydroxyglutaric aciduria, AG-221 and AG-120. The comany was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.